Recombinant Antibodies for Cancer Immunotherapy

Recombinant antibodies have made a tremendous impact
on biomedical research and are increasingly being
used as clinical diagnostic and therapeutic
reagents. The discovery of the tumor markers, opened
a new era in the development of antibody-targeted
cancer therapy. This book evaluates the potential of
recombinant derivatives of an anti-MUCI and an anti-
ErbB2 Mabs to serve as tools for breast cancer
detection and therapy. To explore the potential of
Mabs in antibody-targeted cancer therapy, a novel
IgG-toxin immunoconjugate is described. This work
provides evidences that bivalent antibody-toxin
molecules (200 kDa) are superior to the
corresponding recombinant monovalent immunotoxins
(69 kDa) in killing tumor cells in culture and human
carcinoma xenografts in nude mice, suggesting that
higher avidity and longer residence time may
outweigh tumor penetration. Although many challenges
must be addressed before the approaches mentioned in
this book become standard tools for cancer therapy,
continued research in this area will feed the
clinical product pipeline and play an increasingly
important role in finding the "magical bullet" for
cancer.

Autorentext

Yariv Mazor born in Israel in 1974, son of Malka and Nisim Mazor. Received a PhD in 2005 from the Department of Biotechnology Tel-Aviv University Israel. 2006-2009 postdoctoral in Chemical Engineering, University of Texas at Austin, USA. In 2009 joined the Department of Antibody Discovery & Protein Engineering at MedImmune, inc. MD, USA.

Klappentext

Recombinant antibodies have made a tremendous impact on biomedical research and are increasingly being used as clinical diagnostic and therapeutic reagents. The discovery of the tumor markers, opened a new era in the development of antibody-targeted cancer therapy. This book evaluates the potential of recombinant derivatives of an anti-MUCI and an anti-ErbB2 Mabs to serve as tools for breast cancer detection and therapy. To explore the potential of Mabs in antibody-targeted cancer therapy, a novel IgG-toxin immunoconjugate is described. This work provides evidences that bivalent antibody-toxin molecules (200 kDa) are superior to the corresponding recombinant monovalent immunotoxins (69 kDa) in killing tumor cells in culture and human carcinoma xenografts in nude mice, suggesting that higher avidity and longer residence time may outweigh tumor penetration. Although many challenges must be addressed before the approaches mentioned in this book become standard tools for cancer therapy, continued research in this area will feed the clinical product pipeline and play an increasingly important role in finding the "magical bullet" for cancer.